Xbrane Biopharma AB (publ)
XBRANE.ST
Price:
$10.762
Market Cap:
$131.98M
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as wel...[Read more]
Industry
Biotechnology
IPO Date
2016-02-03
Stock Exchange
STO
Ticker
XBRANE.ST
PE Ratio
[-0.72]
ROE
[28.79%]
Current Ratio
[3.47]
Dividend Yield
[0%]
Enterprise Value
[38.42M]
Dividend History
The ROE as of December 2025 (TTM) for Xbrane Biopharma AB (publ) (XBRANE.ST) is 28.79%
According to Xbrane Biopharma AB (publ)’s latest financial reports and current stock price. The company's current ROE is 28.79%. This represents a change of 531.55% compared to the average of 4.56% of the last 4 quarters.
Xbrane Biopharma AB (publ) (XBRANE.ST) Historical ROE (quarterly & annually)
How has XBRANE.ST ROE performed in the past?
The mean historical ROE of Xbrane Biopharma AB (publ) over the last ten years is -74.06%. The current 28.79% ROE has changed -138.87% with respect to the historical average. Over the past ten years (40 quarters), XBRANE.ST's ROE was at its highest in in the September 2018 quarter at 52.47%. The ROE was at its lowest in in the December 2023 quarter at -91.94%.
Average
-74.06%
Median
-47.54%
Minimum
-226.56%
Maximum
-15.93%
Xbrane Biopharma AB (publ) (XBRANE.ST) ROE by Quarter and Year
Discovering the peaks and valleys of Xbrane Biopharma AB (publ) ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 470.24%
Maximum Annual ROE = -15.93%
Minimum Annual Increase = -68.65%
Minimum Annual ROE = -226.56%
| Year | ROE | Change |
|---|---|---|
| 2024 | -127.66% | -43.65% |
| 2023 | -226.56% | 458.93% |
| 2022 | -40.53% | -8.38% |
| 2021 | -44.24% | -49.73% |
| 2020 | -88.00% | -3.14% |
| 2019 | -90.86% | 470.24% |
| 2018 | -15.93% | -68.65% |
| 2017 | -50.83% | 63.84% |
| 2016 | -31.02% | 24.43% |
| 2015 | -24.93% | -38.95% |
Xbrane Biopharma AB (publ) (XBRANE.ST) Average ROE
How has XBRANE.ST ROE performed in the past?
The current ROE of Xbrane Biopharma AB (publ) (XBRANE.ST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-131.58%
5-year avg
-105.40%
10-year avg
-74.06%
Xbrane Biopharma AB (publ) (XBRANE.ST) ROE vs. Peers
How is XBRANE.ST’s ROE compared to its peers?
Xbrane Biopharma AB (publ)’s ROE is greater than Scandinavian ChemoTech AB (publ) (-192.64%), greater than Biovica International AB (publ) (-118.95%), greater than Nanologica AB (publ) (-82.60%), greater than Alzinova AB (publ) (-21.31%), greater than Active Biotech AB (publ) (-223.35%), greater than Biosergen AB (-94.47%), greater than SciBase Holding AB (publ) (-248.61%), greater than Neola Medical AB (publ) (-14.05%), greater than NextCell Pharma AB (-64.37%), greater than AcuCort AB (-41.59%),
| Company | ROE | Market cap |
|---|---|---|
| -192.64% | $107.95M | |
| -118.95% | $72.16M | |
| -82.60% | $63.45M | |
| -21.31% | $155.02M | |
| -223.35% | $55.36M | |
| -94.47% | $101.44M | |
| -248.61% | $151.84M | |
| -14.05% | $86.52M | |
| -64.37% | $74.41M | |
| -41.59% | $135.51M |
Build a custom stock screener for Xbrane Biopharma AB (publ) (XBRANE.ST) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xbrane Biopharma AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Xbrane Biopharma AB (publ) (XBRANE.ST) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Xbrane Biopharma AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Xbrane Biopharma AB (publ)'s ROE?
How is the ROE calculated for Xbrane Biopharma AB (publ) (XBRANE.ST)?
What is the highest ROE for Xbrane Biopharma AB (publ) (XBRANE.ST)?
What is the 3-year average ROE for Xbrane Biopharma AB (publ) (XBRANE.ST)?
What is the 5-year average ROE for Xbrane Biopharma AB (publ) (XBRANE.ST)?
How does the current ROE for Xbrane Biopharma AB (publ) (XBRANE.ST) compare to its historical average?